BackFidelity Select Biotechnology Portfolio Overview

Fidelity Select Biotechnology Portfolio Receivables

Track Fidelity Select Biotechnology Portfolio's receivables ($17M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$17.19M

Peer trimmed avg / median

Loading

Fidelity Select Biotechnology Portfolio Receivables History

Loading

Fidelity Select Biotechnology Portfolio vs. peers: Receivables Comparison

Loading

Fidelity Select Biotechnology Portfolio Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Fidelity Select Biotechnology Portfolio (FBIOX) FAQ

Fidelity Select Biotechnology Portfolio's receivables stands at $17M as of October 2023. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether Fidelity Select Biotechnology Portfolio's receivables is expanding or contracting. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Fidelity Select Biotechnology Portfolio's receivables evolved across reporting periods, while the comparison chart places FBIOX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.